NCT06793280Completed
Evaluation of Colonic Perfusion by Indocyanine Green Angiography During Colorectal Surgery
Evaluation of Colonic Perfusion by Indocyanine Green Angiography During Elective Colorectal Surgery: Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
Despite advancements in technology and improved surgical techniques, the occurrence of anastomotic leakage (AL) after colorectal surgery remains between 4% and 30%. AL is a feared complication associated with significant morbidity and mortality in colorectal surgery, with its causes being multifaceted. Inadequate blood supply to the intestines is believed to be a major contributor to its development. Various methods have been proposed to objectively assess intestinal perfusion beyond the subjective evaluation done by surgeons during surgery. However, these methods face challenges such as poor reproducibility and high costs, limiting their routine use. In recent years, indocyanine green (ICG) angiography has emerged as a tool for assessing organ perfusion in various medical scenarios. However, only one randomized clinical trial has been conducted regarding its use in evaluating colorectal surgery outcomes, which found that while ICG angiography sometimes led to additional bowel resection, it didn't significantly reduce the rate of anastomotic leaks compared to conventional methods. This could be due to the trial's small sample size, potentially reducing its statistical power. This study aims to investigate whether ICG angiography can lower the rate of anastomotic leaks during laparoscopic colorectal cancer surgery, while also examining its impact on resection margins, perioperative morbidity, and mortality rates. A total of 561 subjects undergoing laparoscopic colorectal surgery for malignancy, will be randomized in 2 arms: A Study Group undergoing ICG angiography (i.e. colonic perfusion is intraoperatively assessed by ICG angiography and level of resection is selected based on the fluorescence) and a Control Group (i.e. resection is performed based on subjective judgment).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 562 (actual)
- First submitted
- 6 May 2024
- Start date
- 22 Feb 2022
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- University of Roma La Sapienza
- Diseases
- Colorectal cancer
- NCT number
- NCT06793280
What you commit to
- Study type: Interventional
- Participants enrolled: 562
- From 22 Feb 2022 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Abdomino-perineal resection
- Conversion to open surgery
- Major vasculopathies (previous PE, DVT, abdominal aorta surgery)
Other illness
- Locally advanced cancer (T4)
- ICG allergy
Other
- Emergency procedures
- No anastomosis
- Multifocal tumors
- Distant metastases (M+)
Who the study is looking for
- Age: 18-85 years
- Malignant colorectal tumors
- Elective surgery
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lidia Castagneto Gissey Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.